Strategic Partnership Announced Between AAOS and OREF

The American Academy of Orthopaedic Surgeons (AAOS) and the Orthopaedic Research and Education Foundation (OREF) announced a strategic partnership to help narrow the gap between clinical research funding and prioritized clinical research needs in musculoskeletal care. The partnership aims to highlight areas of clinical research for which there is a need for increased, targeted funding to evaluate the effectiveness of various orthopedic interventions and ultimately improve the quality of care for patients.

“Orthopaedic surgeons rely on the AAOS clinical practice guidelines to provide high-quality, unbiased evidence-based recommendations for a variety of musculoskeletal treatments. However, there are several orthopedic interventions for which there is a dearth of evidence evaluating their effectiveness,” said Kristy Weber, MD, FAAOS, AAOS past president. “Together with our partners at OREF, we have designed a unique funding opportunity for clinical researchers looking to design and execute studies across musculoskeletal specialties­­, including orthobiologics. To help jump-start the effort in 2020, the AAOS is making an initial financial investment.”

The inaugural list of clinical research topics prioritized by the AAOS includes research addressing the efficacy of biologics for the treatment of orthopedic diseases with a particular focus on platelet-rich plasma and growth factor injections for full-thickness rotator cuff tears and osteoarthritis of the knee. Additionally, the AAOS has prioritized funding for clinical research reviewing the effect of tobacco, vaping, and/or marijuana use on postoperative outcomes for total joint arthroplasty, as well as the effectiveness of antibiotic bone cement for prevention of periprosthetic joint infections. The OREF Research Grants Committee will finalize the selection of topics in the Request for Applications (RFA) scheduled to be released later this year.

“OREF was founded on the belief that to advance orthopedic practice, we must advance orthopedic knowledge,” said Richard F. Kyle, MD, OREF president. “We are delighted to collaborate with the AAOS to fund investigational grants that will catalyze research and play a key role in the future of orthopedic care.”

For more information about the AAOS’ quality programs and guidelines, including the AAOS’ recent investment in evidence-based educational content and symposia for orthobiologics, visit AAOS.org/quality. Donors interested in earmarking funds to further enable AAOS-prioritized clinical research needs within musculoskeletal healthcare can contribute to the OREF/AAOS Clinical Research Gaps Fund. Go to oref.org/aaoscpg to make a secure online donation.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”